{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:27:58Z","timestamp":1792686478061,"version":"4.5.0"},"reference-count":12,"publisher":"Spandidos Publications","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Ther Med"],"DOI":"10.3892\/etm.2025.12859","type":"journal-article","created":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T12:06:22Z","timestamp":1743595582000},"page":"1-4","source":"Crossref","is-referenced-by-count":2,"title":["Lung cancer with diabetes mellitus and polymyalgia rheumatica during long\u2011term nivolumab treatment: A case report"],"prefix":"10.3892","volume":"29","author":[{"given":"Makoto","family":"Nakao","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Kainan Hospital Aichi Prefectural Welfare Federation of Agricultural Cooperatives, Yatomi, Aichi 498\u20118502, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayami","family":"Hirano","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Kainan Hospital Aichi Prefectural Welfare Federation of Agricultural Cooperatives, Yatomi, Aichi 498\u20118502, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Nakai","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Kainan Hospital Aichi Prefectural Welfare Federation of Agricultural Cooperatives, Yatomi, Aichi 498\u20118502, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syuntaro","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Kainan Hospital Aichi Prefectural Welfare Federation of Agricultural Cooperatives, Yatomi, Aichi 498\u20118502, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamiko","family":"Kuriyama","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Kainan Hospital Aichi Prefectural Welfare Federation of Agricultural Cooperatives, Yatomi, Aichi 498\u20118502, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihisa","family":"Takeda","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Kainan Hospital Aichi Prefectural Welfare Federation of Agricultural Cooperatives, Yatomi, Aichi 498\u20118502, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Muramatsu","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Kainan Hospital Aichi Prefectural Welfare Federation of Agricultural Cooperatives, Yatomi, Aichi 498\u20118502, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2025,4,2]]},"reference":[{"key":"key20250513112332_b1-ETM-29-6-12859","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2018.10.017","article-title":"Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials","volume":"107","author":"Kanjanapan","year":"2019","journal-title":"Eur J Cancer"},{"key":"key20250513112332_b2-ETM-29-6-12859","doi-asserted-by":"publisher","first-page":"339","DOI":"10.4143\/crt.2020.790","article-title":"The pattern of time to onset and resolution of immune-related adverse events caused by immune checkpoint inhibitors in cancer: A pooled analysis of 23 clinical trials and 8,436 patients","volume":"53","author":"Tang","year":"2021","journal-title":"Cancer Res Treat"},{"key":"key20250513112332_b3-ETM-29-6-12859","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1001\/jamaoncol.2023.1891","article-title":"Association between duration of immunotherapy and overall survival in advanced non-small cell lung cancer","volume":"9","author":"Sun","year":"2023","journal-title":"JAMA Oncol"},{"key":"key20250513112332_b4-ETM-29-6-12859","doi-asserted-by":"publisher","first-page":"5309","DOI":"10.1016\/j.cell.2021.09.020","article-title":"Hallmarks of response, resistance, and toxicity to immune checkpoint blockade","volume":"184","author":"Morad","year":"2021","journal-title":"Cell"},{"key":"key20250513112332_b5-ETM-29-6-12859","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s13340-018-0362-2","article-title":"Characteristics and clinical course of type 1 diabetes mellitus related to anti-programmed cell death-1 therapy","volume":"10","author":"Baden","year":"2018","journal-title":"Diabetol Int"},{"key":"key20250513112332_b6-ETM-29-6-12859","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.ejca.2017.05.032","article-title":"Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1\/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis","volume":"82","author":"Le Burel","year":"2017","journal-title":"Eur J Cancer"},{"key":"key20250513112332_b7-ETM-29-6-12859","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1136\/annrheumdis-2017-212257","article-title":"Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: A single-centre prospective cohort study","volume":"77","author":"Kostine","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"key20250513112332_b8-ETM-29-6-12859","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.amjms.2021.04.010","article-title":"Nivolumab-Induced polymyalgia rheumatica in a patient with lung adenocarcinoma","volume":"362","author":"Kita","year":"2021","journal-title":"Am J Med Sci"},{"key":"key20250513112332_b9-ETM-29-6-12859","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1093\/rheumatology\/keae099","article-title":"Immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: Comparison of disease characteristics and treatment requirement","volume":"64","author":"Vermeulen","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"key20250513112332_b10-ETM-29-6-12859","doi-asserted-by":"publisher","first-page":"3863","DOI":"10.1200\/JCO.20.00131","article-title":"Continuous versus 1-year fixed-duration nivolumab in previously treated advanced non-small-cell lung cancer: CheckMate 153","volume":"38","author":"Waterhouse","year":"2020","journal-title":"J Clin Oncol"},{"issue":"17588359231195600","key":"key20250513112332_b11-ETM-29-6-12859","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231195600","article-title":"Pursuit or discontinuation of anti-PD1 after 2 years of treatment in long-term responder patients with non-small cell lung cancer","volume":"15","author":"Ardin","year":"2023","journal-title":"Ther Adv Med Oncol"},{"issue":"165","key":"key20250513112332_b12-ETM-29-6-12859","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0645-6","article-title":"Delayed immune-related events (DIRE) after discontinuation of immunotherapy: Diagnostic hazard of autoimmunity at a distance","volume":"7","author":"Couey","year":"2019","journal-title":"J Immunother Cancer"}],"container-title":["Experimental and Therapeutic Medicine"],"original-title":[],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T08:23:38Z","timestamp":1747124618000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/etm.2025.12859"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,2]]},"references-count":12,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,4,2]]}},"URL":"https:\/\/doi.org\/10.3892\/etm.2025.12859","relation":{},"ISSN":["1792-0981","1792-1015"],"issn-type":[{"value":"1792-0981","type":"print"},{"value":"1792-1015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,2]]}}}